Soman

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

PyroGenesis Announces $360,000 Initial Contract for a Plasma-Based PACWAD System for Chemical Warfare Waste Destruction

Retrieved on: 
Tuesday, October 24, 2023
Sarin, 0 A.D. (video game), Plasma, Conventional weapon, FRA, Pollution, Soman, ICEX: US Navy Mission in Arctic, Farm, Wind, Mustard gas, Transport, Mineral, Client, USS Gerald R. Ford, GHG, VX, United States Navy, Forest Law Enforcement and Governance Program, European, Greenhouse, TSX, Renewable energy, Environmental remediation

The contract includes a 45% upfront payment of the total contract value, or 112,500 € (approximately CA$160,000), which has already been received.

Key Points: 
  • The contract includes a 45% upfront payment of the total contract value, or 112,500 € (approximately CA$160,000), which has already been received.
  • Under this agreement, as part of a potential three-phase project PyroGenesis will first provide a lab-scale size plasma arc chemical warfare agent destruction system (the “PACWADS”) as part of a multi-partner project aimed at identifying, extracting, and disposing of chemical munitions and chemical warfare agents residing in active marine passageways and corridors.
  • The eventual goal is to develop a full-scale system once results from the lab-scale system are reviewed.
  • Plasma torches as a waste destruction application are part of the Company’s Waste Remediation tier, encompassing the safe destruction of hazardous materials, and the recovery and valorization of underlying substances such as chemicals and minerals.

Decent Adds One Medical, Doubling its Direct Primary Care Network for Texas Small Businesses

Retrieved on: 
Monday, October 17, 2022
Health, HR, Insurance, Health care, Growth, DPC, Kaiser Family Foundation, PEO, Partnership, 1Life Healthcare, Small business, CEO, Bank account, Medicine, Soman, Professional employer organization, Solution, Prescription, Compliance, Health insurance, Decent work

AUSTIN, Texas, Oct. 17, 2022 /PRNewswire/ -- Decent , Inc., an Austin-based PEO providing small businesses affordable benefits, payroll, and human resource solutions, has doubled its network of direct primary care providers through a new partnership with One Medical .

Key Points: 
  • AUSTIN, Texas, Oct. 17, 2022 /PRNewswire/ -- Decent , Inc., an Austin-based PEO providing small businesses affordable benefits, payroll, and human resource solutions, has doubled its network of direct primary care providers through a new partnership with One Medical .
  • Direct primary care, or DPC, is a membership model of primary care that removes the need for claims and other administrative work tied to traditional health insurance's fee-for-service structure.
  • "That's the foundation of direct primary care, and we're proud to offer small businesses some of the first health plans built around this high-touch style of patient care."
  • Decent offers an employer benefits package that includes One Medical providers as an in-network choice for direct primary care.

Texas-Based Decent Takes on Small Business Monsters in New Ad Campaign

Retrieved on: 
Tuesday, October 4, 2022
Solution, Small business, Time, Professional employer organization, Soman, Nickel, Bigfoot, PEO, CEO, Health, Health insurance, Decent work

Decent , an Austin-based professional employer organization (PEO) offering small businesses benefits, payroll, and compliance help, personified these small business stressors in a new ad campaign, " No More Small Business Monsters ."

Key Points: 
  • Decent , an Austin-based professional employer organization (PEO) offering small businesses benefits, payroll, and compliance help, personified these small business stressors in a new ad campaign, " No More Small Business Monsters ."
  • "If you've run a small business or startup, you know these nuisance monsters inevitably taking away time and resources from running your business," describes Nick Soman, CEO and founder of Decent, and three-time small business owner himself.
  • No More Small Business Monsters is the first large-scale campaign for the Austin, Texas-based startup since it transitioned into a PEO at the end of 2021.
  • Red Tape Worm : This Small Business Monster uses its long and winding body to confuse small business owners, forcing them to jump through hoops until they've exhausted themselves.

Spora Health Partners with Decent to Provide Culturally Competent Primary Care for People of Color in Texas

Retrieved on: 
Tuesday, March 1, 2022
Color, Partnership, Population, PEO Soldier, DPC, Curriculum, Hand, Industry, Soman, Decent work, Founder, PEO, NPS, SAN, Telehealth, Patient, CEO, Health, Health insurance, Medicine

SAN FRANCISCO, March 1, 2022 /PRNewswire/ -- Spora Health , a telemedicine platform offering primary care services for people of color, today announced a partnership with Decent , an affordable health insurance provider for self-employed professionals and their families.

Key Points: 
  • SAN FRANCISCO, March 1, 2022 /PRNewswire/ -- Spora Health , a telemedicine platform offering primary care services for people of color, today announced a partnership with Decent , an affordable health insurance provider for self-employed professionals and their families.
  • "The work Spora Health is doing to provide tailored care to an underserved population is a mission that Decent strongly supports," said Nick Soman, Decent's CEO and Founder.
  • Spora Health is a virtual healthcare provider that empowers people of color to navigate their healthcare journey.
  • Founded in 2020 by Dan Miller, Spora Health is designed to improve lives with culturally-centered primary care.

First Dollar Raises $14 Million in Series A Funding Led by Blue Venture Fund

Retrieved on: 
Thursday, January 27, 2022
Technology, Finance, Professional Services, Software, Practice Management, Managed Care, Health, General Health, Data Management, BCBS, Health, First-dollar gross, Blue Cross Blue Shield Association, Solution, UX, HSAS, TPA, Rx, NPS, API, Industry, Currency strap, Association, Soman, Health insurance, Colin, Sandbox, First Dollar, the Blue Venture Fund, FIRST DOLLAR, THE BLUE VENTURE FUND

First Dollar , the health wallet for modern, member-first plans, today announced it has closed a $14M Series A funding round led by Blue Venture Fund, a unique collaboration among Blue Cross Blue Shield (BCBS) companies, the Blue Cross Blue Shield Association, and Sandbox, to which thirty-five BCBS companies have committed over $890 million across four funds.

Key Points: 
  • First Dollar , the health wallet for modern, member-first plans, today announced it has closed a $14M Series A funding round led by Blue Venture Fund, a unique collaboration among Blue Cross Blue Shield (BCBS) companies, the Blue Cross Blue Shield Association, and Sandbox, to which thirty-five BCBS companies have committed over $890 million across four funds.
  • Blue Venture Fund is joined in the round by existing investors Next Coast Ventures and Meridian Street Capital.
  • The Blue Venture Fund is a unique collaboration among Blue Cross Blue Shield Association, an association of Blue Cross Blue Shield companies, BCBS companies, and Sandbox to which thirty-five BCBS companies have committed over $890 million across four funds.
  • Sandbox is an independent company that provides healthcare-related investment management exclusively for the Blue Venture Fund.

Healthcare Start-Up Decent Expands Small Business Benefits, Relaunches as PEO

Retrieved on: 
Tuesday, October 19, 2021
Soman, COVID-19, Â, PEO, TPA, Professional employer organization, HR, Kaiser Family Foundation, Association, Education, Gusto, TFA, GLOBE, Health, Industry, Founder, Headache, Solution, Health insurance

Today particularly as COVID-19 cases fluctuate small businesses and entrepreneurs are struggling with rising benefits costs such as payroll management and healthcare coverage.

Key Points: 
  • Today particularly as COVID-19 cases fluctuate small businesses and entrepreneurs are struggling with rising benefits costs such as payroll management and healthcare coverage.
  • More affordable payroll and health insurance can safeguard small businesses, said Nick Soman , Decent CEO and Founder.
  • Decent TPA customizes its health plans to drive down costs and reduce healthcare premiums by as much as 35 percent.
  • As a PEO, Decent can further support small businesses by adding payroll management and an intuitive human resources platform.

Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure

Retrieved on: 
Tuesday, May 7, 2019
Health, Biotechnology, Pharmaceutical, Other Health, Research, Science, General Health, Acetylcholinesterase inhibitors, Organ systems, Neurology, Soman, Neuroprotection, Medical specialties, Nerve agent, Brain damage, Erythropoietin in neuroprotection

We are very pleased that the results of our study support the use of RYANODEX as a neuroprotective therapy in nerve agent exposure.

Key Points: 
  • We are very pleased that the results of our study support the use of RYANODEX as a neuroprotective therapy in nerve agent exposure.
  • Eagle conducted an initial study in 2017 to evaluate the neuroprotective effects of RYANODEX in a rodent model of NA-induced brain damage.
  • Positive results of this study led to this GLP study to evaluate the efficacy of RYANODEX to reduce neuropathology in catheterized rats exposed to the nerve agent soman.
  • The animal study was conducted in a rat model of acute nerve agent (soman) exposure.